RIOT

#1115
Riot Platforms, Inc. - Common Stock
18.5 6 USD
+0.04%
Market Price
Sektor: Finanzen
Basis: USD
Gewinnwährung: USD
Tagesspanne
18.04
18.56
Jahresspanne
11.50
30.32
Tagesänderung
+4.33%
Monatliche Änderung
-5.40%
6 month change
+16.58%
Jahresänderung
+30.34%
Vorheriger Schlusskurs
17.7 9
Open
18.1 2
Tief
18.0 4
Hoch
18.5 6
Volumen
1 889
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Riot Platforms, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Riot Platforms, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Riot Platforms, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Riot Platforms, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K

Riot Platforms, Inc. current report, Q2 FY2010

Full document

SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on April 30, 2010. The filing discloses the entry into a Material Definitive Agreement regarding a registered direct offering of securities. Note: The request metadata referenced "Riot Platforms, Inc.", but the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.

Key Financial Metrics and Transaction Details

The Company entered into a Placement Agent Agreement with Lazard Capital Markets LLC for the sale of up to 2,409,639 Units. Each Unit consists of one share of Common Stock and one warrant to purchase 0.285 shares of Common Stock.

  • Gross Proceeds: Approximately $10.0 million.
  • Net Proceeds: Approximately $9.15 million (after fees and expenses).
  • Offering Price: $4.15 per Unit.
  • Warrant Exercise Price: $4.82 per share.
  • Warrant Expiration: Eight (8) months from the closing date.
  • Expected Closing Date: On or about May 5, 2010.

The filing text does not provide current revenue, profit, cash flow, margins, or debt levels, as this is a transactional report rather than a periodic financial statement.

Material Changes and Outlook

The primary material change is the execution of the offering agreement, which is expected to increase the Company's liquidity by approximately $9.15 million upon closing. The offering is being conducted pursuant to a shelf registration statement previously declared effective by the SEC. No specific guidance, management commentary on operational outlook, or discussion of risks beyond standard closing conditions is provided in this specific filing text.

Investor Verification Checklist

  • Verify the final closing date of the offering (expected May 5, 2010) and confirm the actual net proceeds received.
  • Review the full text of the Placement Agent Agreement (Exhibit 1.1) and Warrant (Exhibit 10.2) for specific covenants and dilution impacts.
  • Confirm the use of proceeds as detailed in the accompanying press release (Exhibit 99.1).
  • Check subsequent filings for the actual number of Units sold, as the agreement covers "up to" 2,409,639 Units.

Nachrichten